

**High burden of viruses and bacterial pathogens drives  
heightened nasal innate immunity in children with and without SARS-CoV-2**

Timothy A. Watkins<sup>1,2</sup>, Nagarjuna R. Cheemarla<sup>1,2#</sup>, Katrin Hänsel<sup>1</sup>, Alex B. Green<sup>1,3</sup>, Julien A.R.  
Amat<sup>1,2</sup>, Richard Lozano<sup>1</sup>, Sarah N. Dudgeon<sup>1</sup>, Marie L. Landry<sup>1</sup>, Wade L. Schulz<sup>1</sup>, Ellen F.  
Foxman<sup>1,2\*</sup>

Affiliations:

<sup>1</sup>Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT 06520

<sup>2</sup>Department of Immunobiology, Yale School of Medicine, New Haven, CT 06520

<sup>3</sup>Department of Pediatrics, Yale New Haven Children's Hospital, New Haven, CT 06520

#Current affiliation: Department of Laboratory Medicine and Pathology, University of  
Washington, Seattle, WA, 98195

\*Lead contact and corresponding author: [ellen.foxman@yale.edu](mailto:ellen.foxman@yale.edu)

## 1 **Summary**

2 Recent work indicates that heightened nasal innate immunity in children may impact SARS-  
3 CoV-2 pathogenesis. Here, we identified drivers of nasal innate immune activation in children  
4 using cytokine profiling and multiplex pathogen detection in 291 pediatric nasopharyngeal  
5 samples from the 2022 Omicron surge. Nasal viruses and bacterial pathobionts were highly  
6 prevalent, especially in younger children (81% of symptomatic and 37% asymptomatic children  
7 overall; 91% and 62% in subjects <5 yrs). For SARS-CoV-2, viral load was highest in young  
8 children, and viral load in single infections or combined viral loads in coinfections best predicted  
9 nasal CXCL10, a biomarker of the mucosal interferon response. Bacterial pathobionts  
10 correlated with high nasal IL-1 $\beta$  and TNF, but not CXCL10, and viral-bacterial coinfections  
11 showed a combined immunophenotype. These findings reveal virus and bacteria as drivers of  
12 heightened nasal innate immunity in children and suggest that frequent host-pathogen  
13 interactions shape responses to respiratory viruses in this age group.

14

## 15 **Introduction**

16 A puzzling feature of the COVID-19 pandemic has been its lower impact in children  
17 compared to adults, prompting a search for unique features of antiviral immunity in the pediatric  
18 age group.<sup>1</sup> Recently, several independent studies found heightened nasal innate immune  
19 activation in children compared to adults with SARS-CoV-2 infection and even in the absence of  
20 SARS-CoV-2 infection.<sup>2-5</sup> Although there was variability among subjects, in general, nasal  
21 transcriptome patterns in children showed heightened expression of both interferon-stimulated  
22 genes (ISGs) and pro-inflammatory cytokines, and increased presence of neutrophils and pro-  
23 inflammatory monocytes in the nasal mucosa.<sup>2-5</sup> Since early SARS-CoV-2 replication relies on  
24 evasion of the interferon response within its target tissue,<sup>6,7</sup> pre-activated nasal innate immunity  
25 in children has been proposed to serve as a mechanism of protection from SARS-CoV-2.  
26 However, the biological drivers of heightened nasal innate immunity in children are unknown; it  
27 is also unclear whether there are distinct patterns of heightened nasal innate immunity with  
28 different functional consequences.

29 While it is possible that heightened nasal innate immunity in children is due to age-  
30 intrinsic biological mechanisms, other observations suggest that these patterns may represent  
31 an interplay between microorganisms in the upper respiratory tract and the developing immune  
32 system. Children are known to have much higher rates of colonization with airway bacterial  
33 pathobionts and more frequent infections with common cold-causing respiratory viruses than  
34 adults, likely due, at least in part, to less well-developed adaptive immune defenses in this age  
35 group.<sup>8,9</sup> Recent epidemiological studies using multiplex virus detection have also found a  
36 surprisingly high rate of viral respiratory infections in asymptomatic children.<sup>10,11</sup> In some  
37 instances, asymptomatic viral and bacterial pathobiont detections have been linked to innate  
38 immune responses in the nasal mucosa.<sup>8,12-14</sup> These observations suggest that higher burdens  
39 of viral and bacterial pathobionts in the upper respiratory tract may be important drivers of the  
40 heightened nasal innate immunity seen in children. If this model is correct, virus and pathobiont

41 loads would be expected to predict the variable nasal immunophenotypes seen within the  
42 pediatric age group.

43 The SARS-CoV-2 Omicron surge from December 25, 2021 – January 29, had the  
44 highest rate of reported COVID-19 cases in the U.S. to date overall across age groups,  
45 including subjects <24 years old.<sup>15-17</sup> The large number of children presenting to our healthcare  
46 system for SARS-CoV-2 testing during this timeframe offered an opportunity to test the  
47 relationship between nasopharyngeal immunophenotypes and nasal viral and bacterial burden  
48 in children. Using comprehensive testing for 19 respiratory pathogens and quantitative  
49 microfluidics-based cytokine assays, we demonstrate distinct patterns of innate immune  
50 activation in pediatric subjects predicted by the type(s) and burden of microbes present in the  
51 nasopharynx. Our results indicate that the high burden of respiratory viruses and bacterial  
52 pathobionts in young children drive distinct patterns of heightened nasal innate immunity in this  
53 age group and alter mucosal responses to SARS-CoV-2.

54

## 55 **Results**

### 56 **Children had high rates of infection with SARS-CoV-2 and other viruses in January 2022.**

57 To better understand mucosal innate immunity during pediatric SARS-CoV-2 infection,  
58 we collected nasopharyngeal swab samples from subjects aged 0-19 years undergoing SARS-  
59 CoV-2 testing at Yale New Haven Hospital from January 11-23, 2022, during the SARS-CoV-2  
60 Omicron surge (**Fig 1**). Samples originated in the pediatric emergency department (E.D.) from  
61 children presenting for symptoms associated with acute respiratory infection or for unrelated  
62 conditions as defined by ICD10 code, and from asymptomatic children undergoing and pre-  
63 operative (pre-op) screening for elective surgery. Among 291 samples meeting the inclusion  
64 criteria, there were 56 symptomatic SARS-CoV-2+ subjects. Of these, only 15 subjects were  
65 admitted to the hospital, including 5 admissions for infection-related symptoms, and 10  
66 admissions attributable to comorbidities.

67 RT-qPCR for 15 common respiratory viruses in 291 samples meeting the inclusion  
68 criteria showed a high prevalence of both SARS-CoV-2 and non-SARS-CoV-2 viruses in  
69 children ages 0-5 years at 54.4% (73/135), with 30.1% (40/135) SARS-CoV-2+ and 27.2%  
70 (37/135) positive for other respiratory viruses, the most prevalent being rhinovirus (RV),  
71 adenovirus (Adeno), and human metapneumovirus (hMPV) (**Fig 2A, Table S1**). Overall, the  
72 median age was significantly lower for virus-positive (2.85 years) than for virus-negative  
73 subjects (9.3 years,  $p < 0.0001$ ), demonstrating the association of young age with a higher  
74 prevalence of viruses in this cohort (**Table 1**).

75

#### 76 **Children had high rates of bacterial pathobiont detection and virus-pathobiont** 77 **codetection.**

78 Next, we performed RT-qPCR for three common bacterial pathobionts known to colonize  
79 the upper respiratory tract and contribute to clinically significant respiratory tract coinfections:  
80 *Moraxella catarrhalis*, *Streptococcus pneumoniae*, and *Haemophilus influenzae*.<sup>18-21</sup> All  
81 pathobionts were detected, with *M. catarrhalis* being the most prevalent (**Fig 2B, Table S1**).  
82 Median age was 2.2 years for pathobiont-positive subjects and 11.4 years for pathobiont-  
83 negative subjects (**Table S2**,  $p < 0.0001$ ). Among children <5 years old, 78% had viruses,  
84 pathobionts, or both, including 90% (70/77) of symptomatic subjects and 62.1% (36/58) of  
85 asymptomatic subjects. In subjects ages 5-19 years, 57% (17/30) of symptomatic and 24%  
86 (31/125) of asymptomatic subjects had viruses and/or pathobionts detected. Overall, these data  
87 reveal the high prevalence of non-SARS-CoV-2 viruses and bacterial pathobionts in the  
88 nasopharynx of children undergoing SARS-CoV-2 testing in January 2022.

#### 89 **CXCL10, a biomarker of the nasal interferon response, negatively correlated with age in** 90 **virus-positive subjects, but not virus-negative subjects.**

91 Previous work from our group showed that the interferon-inducible protein CXCL10 is a  
92 robust biomarker of the nasal interferon response, and that CXCL10 levels in the

93 nasopharyngeal swab-associated viral transport media correlate directly with ISG expression by  
94 RNA-seq.<sup>22,23</sup> Therefore, to estimate activation of the mucosal interferon response in the upper  
95 respiratory tract, we measured nasopharyngeal swab-associated CXCL10 protein across all  
96 samples in the dataset using a clinical-grade microfluidics system.<sup>24,25</sup> Nasopharyngeal CXCL10  
97 showed a significant negative correlation with age overall (**Fig 3A, dashed line**) driven  
98 exclusively by virus-positive samples (**Fig 3A, black line**). In contrast, nasopharyngeal CXCL10  
99 showed no correlation with age in virus-negative children (**Fig 3A, grey line**). These results  
100 indicate that the heightened nasal interferon responses in young children are associated with  
101 presence of a viral infection.

102

103 **Viral load, not age, is the major driver of heightened nasal interferon response in children**  
104 **positive for any virus and in children positive for SARS-CoV-2.**

105 Next, we examined viral load using the cycle threshold (Ct) value from RT-qPCR testing.  
106 A lower Ct value represents a higher viral load, with each unit of change representing a 2-fold  
107 difference in viral genome copies detected. In subjects positive for any virus, amount of  
108 nasopharyngeal CXCL10 was significantly associated with virus detection (**Fig 3B**;  $p < 0.0001$ )  
109 and correlated with viral load (**Fig 3C**;  $r^2 = 0.4059$ ,  $p < 0.0001$ ). We observed significant negative  
110 correlations between nasopharyngeal CXCL10 and age ( $r^2 = 0.0876$ ,  $p < 0.0001$ ) and between  
111 viral load and age ( $r^2 = 0.1569$ ,  $p < 0.0001$ ) (**Fig 3D-E**). A positive correlation between CXCL10  
112 and viral load and negative correlations between age and CXCL10 or viral load were also  
113 observed for subjects with SARS-CoV-2 and no other virus (**Fig 3F-H**). For subjects with  
114 seasonal respiratory viruses only, viral loads also correlated significantly with CXCL10, and  
115 CXCL10 and viral load both tended to be higher with younger age, but this trend was not  
116 significant due to a limited number of samples with non-SARS-CoV-2 viruses in subjects  $> 5$   
117 years (**Fig S1A-C**).

118 We applied mediation analysis with multiple regression to evaluate the effects of viral  
119 load as a mediator of the relationship between age and nasopharyngeal CXCL10 level.<sup>26</sup> For  
120 virus-positive samples overall (**Fig 3I**) and for SARS-CoV-2 single infections only (**Fig 3J**) viral  
121 load fully mediated the effect on CXCL10 level. Bootstrapping analysis confirmed this result with  
122 an average causal mediation effect of -0.05 (95% CI [-0.08, -0.03],  $p < 0.001$ ) for all virus-positive  
123 samples and of -0.05 (95% CI [-0.09, -0.02],  $p = 0.002$ ) for SARS-CoV-2-positive samples. These  
124 results indicate that the higher nasal CXCL10 levels observed here in younger virus-positive  
125 children are due to a confounding effect of higher viral loads in younger children rather a direct  
126 age-intrinsic effect on the mucosal interferon response.

127

128 **Coinfection with another respiratory virus in SARS-CoV-2+ subjects is associated with a**  
129 **more robust mucosal antiviral response than predicted by SARS-CoV-2 viral load alone.**

130 Of the 65 SARS-CoV-2+ pediatric subjects we observed, 8 subjects had a coinfecting  
131 respiratory virus (**Table S1**). To evaluate the impact of viral coinfection on the mucosal  
132 interferon response, we compared nasal CXCL10 level to viral load for subjects with only SARS-  
133 CoV-2 detected (**Fig 4A, grey dots**) to subjects with viral coinfections (**Fig 4A, colored dots**).  
134 In subjects with SARS-CoV-2 viral coinfections, CXCL10 values were above the regression line  
135 between SARS-CoV-2 viral load and CXCL10 in single infections, suggesting more robust  
136 activation of the mucosal interferon response in coinfections (**Fig 4A**). The distance from the  
137 regression line was greatest for samples with high viral loads of coinfecting viruses including  
138 influenza A (Ct 21.5, Ct 17.2, Ct 18.6) or RSV (Ct 19.48), and low viral loads of SARS-CoV-2  
139 (Ct 33.1, Ct 36.1, Ct 27.5, Ct 33.9). CXCL10 values fell much closer to values expected for  
140 SARS-CoV-2 single infections when subjects had high viral loads of SARS-CoV-2 and low viral  
141 loads of coinfecting viruses. These results reveal that some children diagnosed with COVID-19  
142 based on a positive SARS-CoV-2 PCR test in fact had low viral loads of SARS-CoV-2 and much

143 higher viral loads of other viral pathogens and suggest that the nasal interferon response during  
144 SARS-CoV-2 infection is driven by the viral load of both SARS-CoV-2 and co-infecting viruses.

145 To further probe whether coinfections impact nasal interferon responses during SARS-  
146 CoV-2 infection, we analyzed RNA-seq data from a previous study showing heightened nasal  
147 innate immunity in SARS-CoV-2+ children (GSE172274), using ISG expression to estimate the  
148 nasal interferon response and metatranscriptomics to identify viral reads as previously  
149 described<sup>2,24,27-29</sup>. Coinfecting viruses were identified in 3/6 children, all <5 years old, including  
150 two subjects with high rhinovirus viral loads (14575 reads per million (rPM) and 1036 rPM) and  
151 SARS-CoV-2 reads near or below the limit of detection from RNA-seq (0.4902 rPM and 0 rPM).  
152 One sample contained reads from the vaccine strain of measles virus consistent with age of the  
153 subject being typical for the first MMR vaccination, and case reports that vaccine measles virus  
154 can be found nasopharynx 7-15 days post-vaccination.<sup>30-32</sup> In contrast, only one viral coinfection  
155 was identified among the 15 adults with nasal RNA-seq data, with low rhinovirus viral load (52  
156 rPM) and high viral load of SARS-CoV-2 (18821.5 rPM). ISG score directly correlated with viral  
157 load in subjects with SARS-CoV-2 and no other virus detected; however, the three children with  
158 non-SARS-CoV-2 viral coinfections had higher ISG scores than expected based on the  
159 relationship between SARS-CoV-2 viral load and ISG score in single infections (**Fig 4B**). While  
160 the number of subjects is limited, these findings support the idea that coinfecting viruses drive  
161 an augmented mucosal interferon response during SARS-CoV-2 infection, and that more  
162 frequent viral coinfections in children may contribute to the previously described heightened  
163 nasal immune responses in SARS-CoV-2-positive children compared to adults.

#### 164 **Bacterial pathobionts alter the nasal mucosal immunophenotype.**

165 We next sought to explore whether bacterial pathobiont detection correlates with  
166 changes in nasal mucosal innate immune activation. For this analysis, we focused on children  
167 under the age of 5 years in whom pathobionts were most prevalent.



168 To select nasopharyngeal biomarkers that might capture pathobiont-induced mucosal  
169 innate immune responses, we examined differentially-enriched transcripts and cytokines from a  
170 previous study in which we identified nasopharyngeal samples from rhinovirus-infected children  
171 and adults, about half of whom showed high loads of bacterial pathobionts based on bacterial  
172 reads in RNA-seq data.<sup>24</sup> Pathways enriched in rhinovirus-positive pathobiont-high samples  
173 compared to rhinovirus-positive pathobiont-low samples indicated leukocyte recruitment,  
174 myeloid cell activation, NFkB-signaling, and interferon signaling (**Fig S2A**). Among the top 10  
175 cytokine regulators of DEGs, 4 were also highly differentially expressed at the mRNA level:  
176 TNF, IL-1 $\beta$ , IL-6, and IL-1 $\alpha$  (**Fig S2B**). Multiplex testing for 71 cytokines in these samples  
177 revealed that TNF and IL-1 $\beta$  were also among the top 10 differentially expressed cytokines in  
178 the nasopharynx at the protein level (**Fig S2C**). IL-1 $\beta$  and TNF were also shown to be  
179 associated with colonization of *M. catarrhalis* and *H. influenzae* in the airway in a prior study of  
180 662 asymptomatic infants, suggesting that bacterial pathobionts also induce these cytokines in  
181 the nasal mucosa without rhinovirus infection, although the presence of viruses was not  
182 assessed in the prior study.<sup>14</sup>

183 To explore TNF and IL-1 $\beta$  as biomarkers of the mucosal innate immune response  
184 induced by bacterial pathobionts, we evaluated relationships between age, pathobionts, and  
185 nasopharyngeal protein levels of IL-1 $\beta$  and TNF in children <5 years. IL-1 $\beta$  was significantly  
186 elevated in pathobiont-only detection and was similarly elevated in virus/pathobiont codetection  
187 (**Fig 5A**). TNF was modestly but significantly elevated in pathobiont-only samples ( $p=0.0224$ )  
188 and enhanced by virus/pathobiont codetection ( $p<0.0001$ ; **Fig 5B**). Pathobiont load in all  
189 pathobiont-positive samples as well as *M. catarrhalis*-only samples correlated directly with IL-1 $\beta$   
190 level, further suggesting pathobiont load is a driver of IL-1 $\beta$  level ( $r^2=0.2843$ ,  $p<0.0001$ ;  
191  $r^2=0.2562$ ,  $p<0.0001$ ) (**Fig 5C-D**). TNF level correlated significantly with pathobiont load in both  
192 virus-positive and virus-negative samples, and the slope of virus-positive samples trended

193 slightly higher, but the difference was not significant ( $p=0.1105$ ) (**Fig 5E**). These data suggest  
194 that nasopharyngeal IL-1 $\beta$  and TNF reflect a pathobiont-induced mucosal inflammatory  
195 response that occurs independently of, but may be enhanced by, viral coinfection.

196 We also explored the impact of pathobiont detection on nasal CXCL10 in the same four  
197 groups. Consistent with the sample set as a whole (**Fig 2**), in children <5 years, we observed  
198 significant elevation in nasal CXCL10 in virus-positive samples compared to virus- and  
199 pathobiont-negative controls regardless of pathobiont detection, but no CXCL10 elevation in  
200 pathobiont-positive, virus-negative subjects. (**Fig 5F**). When limiting the analysis to  
201 asymptomatic children, nasal CXCL10 was also elevated in virus-positive compared to virus-  
202 negative subjects, although asymptomatic subjects had lower viral loads and CXCL10 levels  
203 than symptomatic subjects (**Fig S3A-B**). Together, these data provide evidence that a robust  
204 mucosal interferon response, as indicated by nasopharyngeal CXCL10 elevation, is triggered by  
205 viral infection but not bacterial pathobionts.

206 Since pathobionts are associated with clinically significant secondary infections following  
207 viral infection, we also explored the relationship between pathobiont detection and viral load.  
208 Among children <5 years of age, neither viral load nor pathobiont load was significantly different  
209 in viral-bacterial codetections compared to single detections, and pathobiont loads and viral  
210 loads did not correlate with each other in codetections (**Fig S3C-E**). We also did not observe a  
211 significant change of nasal immunophenotypes defined by IL-1 $\beta$ , TNF, and CXCL10 levels  
212 attributed to patient sex in this age group (**Fig S4A-C**). Together, these findings indicate that  
213 both viruses and bacterial pathobionts promote heightened nasal innate immunity in young  
214 children, and that viruses and pathobionts drive distinct patterns of heightened nasal innate  
215 immunity.

216

217 **Biomarkers demonstrate heightened nasal innate immunity in children <5 years old with**  
218 **distinct patterns related to viral and bacterial pathobiont burden.**

219 To explore associations of age, viruses, pathobionts, and symptoms with nasal  
220 immunophenotypes in children <5 years of age, we generated scatterplots based on  
221 concentrations of CXCL10 and IL-1 $\beta$ , the nasopharyngeal biomarkers best associated with viral  
222 infection and bacterial pathobionts respectively. Within the 0-5 years age group, age did not  
223 appear to correlate with cytokine responses (**Fig 5G**). In contrast, plots highlight a strong  
224 association between viral load and nasopharyngeal CXCL10 and between bacterial load and  
225 nasopharyngeal IL-1 $\beta$  (**Fig 5H-I**). Children presenting to the E.D. with symptoms of acute  
226 respiratory infection separated into a CXCL10-high and IL-1 $\beta$  low-to-high phenotype, indicating  
227 that viral infection was highly associated with symptomatic presentation (**Fig 5J**). Among virus-  
228 positive subjects <5 years old, symptomatic subjects and asymptomatic subjects were equally  
229 likely to be pathobiont-positive suggesting that pathobiont detection was not a strong influence  
230 on symptomatic presentation (**Table S2**). However, virus-positive, pathobiont-positive subjects  
231 did have an enhanced mucosal inflammatory response as indicated by trend toward higher  
232 nasal TNF in subjects with viral/pathobiont codetection compared to those with virus or  
233 pathobiont only (**Fig 5B, E**). Taken together, these analyses show that viruses and nasal  
234 bacterial pathobionts are associated with distinct patterns of heightened mucosal innate  
235 immunity, alone and in combination, compared to age-matched virus-negative, bacteria-  
236 negative controls.

## 237 **Discussion**

238           Innate immune defenses at the site of infection are critically important in limiting  
239 susceptibility to respiratory viruses, particularly in the case of emerging viruses such as SARS-  
240 CoV-2 when there is no prior adaptive immunity. Here we show a clear relationship between  
241 viral presence and abundance in the upper respiratory tract and activation of the interferon  
242 response, a potent antiviral defense pathway. We also show a link between bacterial pathobiont  
243 burden and activation of pro-inflammatory nasal mucosal responses. Together with prior  
244 studies, these results point to a high burden of respiratory viruses and bacterial pathobionts in  
245 children and link these mucosal pathogens with heightened nasal innate immunity. Our results  
246 also highlight examples of viral-viral and viral-bacterial coinfections which illustrate that the host  
247 response to one microbe influences the mucosal response to another in the airway niche.

248           A key feature of our study was performing PCR testing targeting 15 seasonal respiratory  
249 viruses and three common bacterial pathobionts in addition to SARS-CoV-2, including samples  
250 from symptomatic and asymptomatic subjects. RT-qPCR is a sensitive and specific assay for  
251 respiratory viruses in clinical samples. In prior studies of pediatric nasal innate immunity,  
252 samples were tested by RT-qPCR for SARS-CoV-2 but not for other respiratory viruses.<sup>2-5</sup> With  
253 RT-qPCR testing for 16 viruses, we found a high burden of seasonal respiratory viruses in  
254 addition to SARS-CoV-2 during the January 2022 Omicron surge that were not diagnosed at the  
255 time of SARS-CoV-2 testing. We were also able to examine the quantitative relationship  
256 between viral loads and mucosal cytokine responses using sensitive microfluidics-based  
257 immunoassays with high accuracy and large dynamic range.<sup>25</sup>

258           Comparing nasal cytokine responses to virus detections and loads in individual samples  
259 revealed viral load as the proximal driver of the nasal interferon response in children. First, in  
260 SARS-CoV-2 single infections or with other respiratory viruses, younger children had  
261 heightened nasal interferon responses, but this was largely due to higher viral loads in younger  
262 children. Examining non-COVID viruses in SARS-CoV2+ subjects revealed coinfections as an

263 explanation for the disparity between SARS-CoV-2 viral load and nasal interferon response in  
264 prior studies. Interestingly, we also found a higher-than-expected nasal interferon response in a  
265 SARS-CoV-2+ young child with nasopharyngeal co-detection of measles vaccine strain virus,  
266 suggesting that live attenuated vaccines may also impact heightened nasal innate immunity in  
267 children. Intuitively, the finding that the upper respiratory tract interferon responses correlate  
268 with viral load fits with the known mechanism of interferon and ISG induction, in which viral RNA  
269 recognition by innate immune sensors initiates the signaling cascade leading the interferon  
270 response.<sup>33</sup>

271         There are several possible reasons for higher prevalence and load of respiratory viruses  
272 among the youngest children in this data set. First, we considered biases in the sample set; for  
273 example, younger children were more likely to present to the ED with acute respiratory illness,  
274 whereas older children were more likely to present for other reasons. However, even among  
275 asymptomatic subjects, the prevalence of both SARS-CoV-2 and seasonal respiratory viruses  
276 was the highest in younger children, suggesting greater susceptibility. Also, young children have  
277 been shown to have higher prevalence of seasonal respiratory viruses than older children and  
278 adults with unbiased sampling. For example, in a year-long study of 26 families which included  
279 weekly nasal sampling agnostic of symptoms, respiratory viruses were detected on average 26  
280 weeks per year in children under 5 with decreasing detection rates for older age groups.<sup>10</sup>

281 Public health interventions drastically reduced circulation of many respiratory viruses during the  
282 first year of the COVID-19 pandemic; however, there is evidence for increased circulation of  
283 rhinoviruses and enteroviruses by June 2020, for adenoviruses, seasonal coronaviruses, and  
284 parainfluenza by early 2021, and other viruses later in 2021.<sup>34</sup> Our results demonstrate high  
285 circulation of diverse non-SARS-CoV-2 viruses in young children by January 2022.

286         The higher susceptibility of young children to seasonal respiratory viruses is generally  
287 attributed to less adaptive immunity due to fewer prior exposures.<sup>35</sup> For SARS-CoV-2, a novel  
288 virus which is thought to have first become widespread in children during the Omicron surge, we

289 were initially surprised to also observe higher prevalence and viral loads in the youngest  
290 children among our study subjects aged 0-19 yrs. While greater adaptive immunity in older  
291 children due to more prior exposure is a possibility, vaccination may have also played a role,  
292 since vaccines were only available to children >5 years old in the U.S. in January 2022.<sup>36,37</sup> It is  
293 also possible that infants and young children were more likely to present for healthcare than  
294 older children with similar symptoms, and symptomatic subjects had higher viral loads. Other  
295 features of upper respiratory tract biology in early life could also play a role. For example, there  
296 is some evidence that unique features of the pediatric nasal mucosa promote replication of  
297 some respiratory viruses based on ex vivo culture.<sup>38</sup>

298         Relevant to understanding the roles of cell intrinsic vs environmental factors in  
299 heightened innate immunity in children, a recent study by Maughan et al. compared airway  
300 mucosa of children and adults in vivo and ex vivo, using both laser capture-microdissection of  
301 biopsies, airway basal cells sorted directly from biopsies, and proliferating primary basal  
302 epithelial cells in culture.<sup>39</sup> RNA sequencing from biopsies and sorted basal cells, which  
303 captured the transcriptome at the time of sampling, recapitulated previous findings from patient  
304 samples, showing that interferon response pathways are elevated in children compared to  
305 adults. However, basal cells cultured in vitro from the same subjects showed a trend toward  
306 lower innate immune activation in epithelial cells derived from children. This study is consistent  
307 with our findings indicating that viruses and bacteria found in the nasal mucosa in vivo, rather  
308 than cell-intrinsic factors, drive heightened respiratory mucosal innate immunity in children.

309         In addition to heightened interferon responses, prior studies using scRNA-seq of patient  
310 samples showed that the pediatric nasal mucosal was enriched for leukocytes, particularly  
311 neutrophils and pro-inflammatory monocytes.<sup>3,4</sup> We observed similar myeloid-rich leukocyte  
312 signatures in nasopharyngeal RNA-seq data from rhinovirus-infected subjects with high levels of  
313 bacterial pathobionts compared to pathobiont-low ,rhinovirus-infected subjects, associated with  
314 increase in nasal IL-1 $\beta$  and TNF proteins. Analysis of samples in this study confirmed nasal IL-

315 1 $\beta$  and TNF as biomarkers of pathobiont-associated inflammation in both virus-negative and  
316 virus-positive subjects. Pathobionts alone did not induce nasal interferon responses, as  
317 indicated by no change in the CXCL10 level, but were associated with a synergistic increase in  
318 TNF. Together, these observations show that pathobionts promote local mucosal inflammatory  
319 responses and may enhance antiviral responses upon viral coinfection.

320 While our study shows a high frequency of pathobionts in young children, it is still  
321 unclear if pathobionts or the inflammatory responses they induce are protective or detrimental in  
322 COVID-19. For seasonal respiratory viruses, bacteria in the genera *Moraxella*, *Haemophilus*,  
323 and *Streptococcus* increase the incidence of infection, disease severity during infection, risk of  
324 lower respiratory tract infection, and later asthma development.<sup>40-43</sup> This evidence is particularly  
325 strong for RSV, influenza, and rhinoviruses.<sup>44,45</sup> We found no difference in SARS-CoV-2+ viral  
326 loads in age-matched pathobiont-positive and pathobiont-negative subjects under the age of 5  
327 years, but SARS-CoV-2+ samples in this age group were almost all from symptomatic subjects  
328 with similar high viral loads. Evaluating this question with unbiased sampling, including  
329 longitudinal studies on children with and without pathobionts at baseline, will provide more  
330 insight into how pathobionts influence SARS-CoV-2 susceptibility and outcomes.

331 Our study also demonstrated high prevalence of respiratory viruses in children and  
332 induction of mucosal interferon responses concomitant with viral load. Together with the prior  
333 literature, our data support a model in which children are highly susceptible to respiratory  
334 viruses but also that frequent host-virus interactions have a net effect of limiting closely spaced  
335 infections by activating mucosal antiviral defenses. Recent experimental evidence for interferon-  
336 mediated interference among respiratory viruses supports this idea. For example, recent work  
337 from our group and others shows that prior infection with rhinovirus and other seasonal  
338 respiratory viruses can induce a robust interferon response that reduces replication of SARS-  
339 CoV-2 or influenza viruses in simultaneous or sequential infections.<sup>23,46-50</sup> Also compelling is a  
340 recent vaccination study by Costa-Martins et. al., which showed that among asymptomatic

341 children ages 2-5 receiving the live attenuated influenza vaccine, 41% had seasonal respiratory  
342 viruses detected, virus detection was associated with a nasal ISG signature, and nasal ISG  
343 expression prior to vaccination correlated with reduced replication of vaccine viruses.<sup>11</sup> While  
344 the outcome of viral coinfections depends on many factors including the viruses involved,  
345 relative timing, and host susceptibility, we propose that when the first infection is well-controlled  
346 by the mucosal interferon response, the effect is likely to be protective, such as in the setting of  
347 asymptomatic or resolving viral infections that are common in young children.

348 In sum, this qualitative and quantitative analysis of respiratory viruses, bacterial  
349 pathobionts, and cytokine biomarkers reveals viruses and bacterial pathobionts as major drivers  
350 of heightened nasal innate immunity in children and compels further study of how seasonal  
351 respiratory viruses and bacterial pathobionts impact SARS-CoV-2 infection in children, including  
352 interactions occurring in asymptomatic subjects.

353

#### 354 **Limitations of the study**

355 Here we measured a targeted panel of cytokine biomarkers, viruses and bacteria in a large  
356 sample set, complementing prior work which used detailed immunophenotyping by RNA-seq  
357 and single cell sequencing albeit in smaller sample sets. We focused on 19 respiratory  
358 microbes, but other less common viruses or nasopharyngeal pathobionts could also contribute  
359 to nasal innate immune activation in children. Future studies pairing detailed  
360 immunophenotyping with sensitive pathogen detection methods and clinical data will provide  
361 further insights into the range of nasal immunophenotypes in children and their drivers.  
362 Additionally, this analysis captured only a small number of viral coinfections with SARS-CoV-2  
363 which suggested that viral coinfections augment the interferon response to SARS-CoV-2, but  
364 further studies are required for confirmation. Finally, we studied a cross-section of samples from  
365 a single time point. Future longitudinal studies tracking how nasal microbes and  
366 immunophenotypes in children impact SARS-CoV-2 infection in will provide further insights into



367 host-pathogen interactions and the consequences of heightened mucosal innate immunity in  
368 children.

## **Resource Availability**

This study did not generate new unique reagents.

## **Lead Contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Ellen Foxman (ellen.foxman@yale.edu).

## **Data and code availability**

All data produced in the present work are contained in the manuscript. Extended data analyses, original code for mediation analysis and data visualizations, and extended demographics data will be deposited in Mendeley Data at the DOI 10.17632/g8ckr9zxbx.1 and will be available at the time of peer-reviewed publication.

## **Experimental procedures**

### **Nasopharyngeal swab collection and inclusion criteria**

In this study, we collected a total of 306 residual nasopharyngeal swab samples from patients presenting to the pediatric emergency department between January 11-23, 2022 and were screened for SARS-CoV-2. 15 samples were excluded from further analysis due to low Ct for the internal control (albumin, Ct>33), leaving 291 samples for analysis. The study protocol was reviewed and approved by the Yale Human Investigation Committee (protocol #2000027656) and was determined to not require specific patient consent.

### **Chart review for symptom designation and admission comorbidities**

To assign symptoms, we extracted, de-identified ICD-10 codes and supplemented with manual chart review. Patients were considered “symptomatic” if the ICD-10 code associated with presentation to the ED are common in respiratory infections. For patients with acute,

symptomatic presentations related to respiratory infections, ICD-10 codes alone were used to ascribe clinical syndromic categories. Where ICD-10 codes for acute, symptomatic presentations were ambiguous (e.g., “Emergency use of U07.1 | COVID-19”), or for clinical samples which were obtained in the preoperative setting, manual chart review by a clinical reviewer blinded to bacterial, viral, and immune biomarker status was conducted for determination of clinical syndromic category. Detailed examination of patients positive for COVID-19 testing and admitted to the inpatient setting were characterized via manual chart review to determine presenting symptoms and comorbidities. In this latter instance, the clinician reviewer was blinded to bacterial status, common respiratory viral status, and biomarker status, but not COVID-19 status.

### **Cytokine measurements**

Viral transport media was thawed on ice before measurement of cytokines and subsequently aliquoted and stored at -80°C for use in other experiments. CXCL10, IL-1 $\beta$ , and TNF proteins were measured using the Ella automated microfluidics system (Protein Simple, San Jose, USA).

### **Clinical Virology Testing**

For testing by the YNH Clinical Virology Laboratory, nasopharyngeal swabs were placed in viral transport media (BD Universal Viral Transport Medium) immediately upon collection for clinical SARS-CoV-2 testing. Viral transport media associated with nasopharyngeal swab was aliquoted and stored at -80°C for further analyses within three days of clinical testing. For virology testing, 200  $\mu$ L of VTM were used for total nucleic acid extraction using the NUCLISENS easyMAG platform (BioMérieux, France). Extracted nucleic acid was tested for a 15-virus panel as described previously.<sup>24</sup> SARS-CoV-2 testing was completed using four clinical testing platforms. When the clinical testing platform did not result in a Ct value for SARS-CoV-2 or the value was unable to be retrieved from medical records, we performed in-lab SARS-CoV-2

qPCR testing as follows: 140 µL of viral transport media was used for viral RNA extraction using the QIAamp Viral RNA Kit (QIAGEN, Venlo, ND). 5 µL of viral RNA eluate was then used to generate cDNA using the iScript cDNA synthesis kit (Bio-Rad, CA, USA). 2 µL of cDNA was then used to test for SARS-CoV-2 using the 2019 CDC SARS-CoV-2 N1 assay (IDT, IA, USA)<sup>51</sup>. If the SARS-CoV-2 E gene Ct value was measured in either the Roche cobas or Cepheid Xpress Xpert test, this value was used for analysis. If the SARS-CoV-2 E gene measurement was not retrieved from the medical record or was not tested on either the Roche or Cepheid platforms, we converted Ct values from other platforms and genes to the SARS-CoV-2 E gene using interpolation of the linear regression between samples with known E genes and other SARS-CoV-2 genes reported. This approach applied to the Roche cobas SARS-CoV-2 ORF1ab test, the Cepheid SARS-CoV-2 N2 test, and the CDC SARS-CoV-2 N1 test. For SARS-CoV-2 and all other respiratory viruses, a Ct value of 40 or above is considered negative.

### **Pathobiont RT-qPCR**

All samples of sufficient quality and sample amount were tested for *Moraxella catarrhalis*, *Haemophilus influenzae*, and *Streptococcus pneumoniae* (n=290). One sample present in the multiplex virus-tested dataset was excluded from pathobiont RT-qPCR due to low sample amount and is not included in immunophenotyping analysis, leaving a sample set of 290. For measurement of pathobionts, 2 µL of total nucleic acid extraction from clinical testing was used for each pathobiont RT-qPCR assay. The AgPath-ID One-Step RT-PCR master mix (Applied Biosystems, MA, USA) was used with commercially available Taqman qPCR assays designed for each pathobiont (ThermoFisher, MA, USA). Thermocycler conditions were set according to the manufacturer's instructions.

### **Quantification and Statistical Analysis**

GraphPad Prism (version 9.5.1; GraphPad Software, San Diego, CA, USA) was used for simple linear regression analyses, Welch's ANOVA tests with Dunnett's T3 multiple comparisons tests, Kruskal-Wallis tests with Dunn's multiple comparisons tests, and unpaired t-tests as specified in figure legends. For mediation analysis, we considered two different viral load categories. First, for all virus-positive individuals (n = 106), we considered the Ct value of the infecting virus for single infections and the minimum Ct value (i.e., highest viral load) virus for individuals identified with coinfections. Second, we focused on individuals with a SARS-CoV-2 single infection (n=57) where only the Ct value of the SARS-CoV-2 test was considered. We followed Baron and Kenny's causal step approach using linear modelling of the effect.<sup>26</sup> Pre-requisites for indicating the appropriateness of the mediation analysis were confirmed by testing for a significant direct effect from the independent variable (IV; i.e., age) towards the dependent variable (DV; i.e., log<sub>10</sub>-transformed CXCL10) and a significant effect of the IV on the mediator (i.e., viral Ct). The mediation effect is then tested by considering the combined effect of the mediator and IV on the DV. In case the significant effect of the IV on the DV is reduced by the inclusion of the mediator, we can positively confirm the mediation. Lastly, casual mediation effects were computed for 1000 bootstrapped samples and the 95% confidence-interval is reported. The analysis was performed using RStudio version 2022.12.0.353 using the stats package 4.1.2 for the linear modelling and mediation 4.5.0 for building the final mediation model and extracting information on the causal mediation effects.<sup>52,53</sup>

## **Data Visualization**

GraphPad Prism (version 9.5.1; GraphPad Software, San Diego, CA, USA) was used to generate graphs for the majority of main and supplemental figures. For figure 5G-H, RStudio (version 4.2.2) software was used.<sup>53</sup> Data curation and preparation was conducted through use of tidyverse (version 2.0.0) and lubridate (version 1.9.2) R packages, while visualization was assisted by the ggplot2 (version 3.4.1) package.<sup>54-56</sup> For figure S2, Ingenuity Pathway Analysis

software (QIAGEN Digital Insights) and Qlucore Omics Explorer (Qlucore) were used to generate graphs and heatmaps. All figures were edited and arranged in Adobe Illustrator (Adobe Inc, Mountain View, CA, USA).

### **RNA-seq Analysis of GSE172274**

RNA-seq analysis of samples deposited in the NIH Gene Expression Omnibus (GEO) database under the accession number GSE172274 was carried out using Partek Flow software (version 10.0) for human transcripts.<sup>2</sup> Samples were aligned to the GRCh38 human genome using Bowtie 2 and quantified using Ensembl Transcripts Release 104.<sup>27,28,57</sup> Counts were normalized as counts per million (CPM) plus 0.0001 for downstream log-scaling analysis. Analysis focused on 50 genes found to be upregulated and differentially expressed in nasal epithelial cells during the antiviral response from a previous dataset.<sup>22</sup> Normalized counts were converted to Z-scores by subtracting the mean expression of each gene across all sample from each sample count and dividing by the standard deviation of the gene's expression across all samples. Finally, the ISG score was calculated by averaging the Z-scores for the 50 listed genes for each sample. Metatranscriptomics analysis of samples in GSE172274 were analyzed using the CZ ID metatranscriptomics pipeline as previously described.<sup>24,29</sup> Non-SARS-CoV-2 respiratory virus reads were considered positive if above 1 read per million (rPM). All samples in this dataset tested positive for SARS-CoV-2 by clinical testing as described previously.<sup>2</sup>

### **Pathobiont Marker Selection and Pathway Analysis**

RNA-seq analysis was performed on datasets available on the NIH Database of Genotypes and Phenotypes (dbGaP) under accession codes phs002442.v1.p1 and phs002433.v1.p1 as previously described.<sup>23,24</sup> Ingenuity pathway analysis (IPA) was carried out using differentially expressed genes (DEGs) between rhinovirus-positive/pathobiont-high and rhinovirus-positive/pathobiont-low samples to identify genes expressed in virus/pathobiont codetection.

Analysis of upstream regulators of DEGs listed in results was filtered on cytokines only. For multiplex protein analysis, Qlucore Omics Explorer was used to identify differentially expressed cytokines. Cytokines with <1 pg/mL expression across all samples were excluded, and remaining cytokines were log<sub>2</sub>-scaled. Finally, two-group comparison between rhinovirus-positive/pathobiont-high and rhinovirus-positive/pathobiont-low samples was used to narrow down to the top 10 differentially expressed cytokines between these groups and are listed in order of significance of the q-value statistic. Only samples that are virus-negative/pathobiont-low, rhinovirus-positive/pathobiont-low and rhinovirus-positive/pathobiont-high are shown.

### **Acknowledgments**

This study was funded by the National Institutes of Health (T32AI055403 received by TAW), Fast Grants for COVID-19 research from the Mercatus Center (George Mason University, Fairfax, VA, USA; received by EFF), the Rita Allen Foundation (received by EFF) and the Gruber Foundation (received by TAW). We thank Bao Wang, Valia Mihaylova, and Hui Jing Lim for helpful discussions; Rolando Garcia-Milian for training and assistance with Partek Flow software, Qlucore Omics Explorer, and Ingenuity Pathway Analysis; the Yale New Haven Hospital clinical virology laboratory for valuable assistance and support.

### **Contributions**

Conceptualization: EFF. Methodology: TAW, NRC, KH, ABG, WLS, EFF. Software: KH, JARA, SND, WLS. Validation: TW, WLS, EFF. Formal Analysis: TAW, KH, JARA, SND. Investigation: TAW, NRC, ABG, RL, EFF. Resources: MLL (nasopharyngeal swabs). Data Curation: TAW, NRC, KH, JARA, and ABG. Writing – Original Draft: TAW and EFF. Writing – Review & Editing: all authors. Visualization: TAW, KH, and JARA. Supervision and Funding Acquisition: EFF.

**Declaration of Interests**

Dr. Foxman is an inventor on a pending patent application WO2019/217296 A1 and provisional patent application No 63/293386. Dr. Foxman and Dr. Landry are inventors on pending patent application WO2018/071498 A1. Dr. Schulz is a consultant for Hugo Health, consultant for Detect Inc, a point-of-care diagnostics company; co-founder of Refacto Health, and has received funds from Merck, Regeneron, the Shenzhen Center for Health Information, and the Beijing National Center for Cardiac Diseases. The other authors declare no competing interests.



## References

1. Kang, S.J., and Jung, S.I. (2020). Age-Related Morbidity and Mortality among Patients with COVID-19. *Infect Chemother* 52, 154-164. 10.3947/ic.2020.52.2.154.
2. Pierce, C.A., Sy, S., Galen, B., Goldstein, D.Y., Orner, E.P., Keller, M.J., Herold, K.C., and Herold, B.C. (2021). Natural mucosal barriers and COVID-19 in children. *JCI Insight*. 10.1172/jci.insight.148694.
3. Loske, J., Rohmel, J., Lukassen, S., Stricker, S., Magalhaes, V.G., Liebig, J., Chua, R.L., Thurmman, L., Messingschlager, M., Seegebarth, A., et al. (2022). Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. *Nat Biotechnol* 40, 319-324. 10.1038/s41587-021-01037-9.
4. Yoshida, M., Worlock, K.B., Huang, N., Lindeboom, R.G.H., Butler, C.R., Kumasaka, N., Dominguez Conde, C., Mamanova, L., Bolt, L., Richardson, L., et al. (2022). Local and systemic responses to SARS-CoV-2 infection in children and adults. *Nature* 602, 321-327. 10.1038/s41586-021-04345-x.
5. Winkley, K., Banerjee, D., Bradley, T., Koseva, B., Cheung, W.A., Selvarangan, R., Pastinen, T., and Grundberg, E. (2021). Immune cell residency in the nasal mucosa may partially explain respiratory disease severity across the age range. *Sci Rep* 11, 15927. 10.1038/s41598-021-95532-3.
6. Park, A., and Iwasaki, A. (2020). Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19. *Cell Host Microbe* 27, 870-878. 10.1016/j.chom.2020.05.008.
7. Minkoff, J.M., and tenOever, B. (2023). Innate immune evasion strategies of SARS-CoV-2. *Nat Rev Microbiol* 21, 178-194. 10.1038/s41579-022-00839-1.
8. Lambert, L., and Culley, F.J. (2017). Innate Immunity to Respiratory Infection in Early Life. *Frontiers in Immunology* 8, 1570. 10.3389/fimmu.2017.01570 PMID - 29184555.

9. Toivonen, L., Hasegawa, K., Waris, M., Ajami, N.J., Petrosino, J.F., Camargo, C.A., Jr., and Peltola, V. (2019). Early nasal microbiota and acute respiratory infections during the first years of life. *Thorax* 74, 592-599. 10.1136/thoraxjnl-2018-212629.
10. Byington, C.L., Ampofo, K., Stockmann, C., Adler, F.R., Herbener, A., Miller, T., Sheng, X., Blaschke, A.J., Crisp, R., and Pavia, A.T. (2015). Community Surveillance of Respiratory Viruses Among Families in the Utah Better Identification of Germs-Longitudinal Viral Epidemiology (BIG-LoVE) Study. *Clin Infect Dis* 61, 1217-1224. 10.1093/cid/civ486.
11. Costa-Martins, A.G., Mane, K., Lindsey, B.B., Ogava, R.L.T., Castro, I., Jagne, Y.J., Sallah, H.J., Armitage, E.P., Jarju, S., Ahadzie, B., et al. (2021). Prior upregulation of interferon pathways in the nasopharynx impacts viral shedding following live attenuated influenza vaccine challenge in children. *Cell Rep Med* 2, 100465. 10.1016/j.xcrm.2021.100465.
12. Wolsk, H.M., Folsgaard, N.V., Birch, S., Brix, S., Hansel, T.T., Johnston, S.L., Kebabze, T., Chawes, B.L., Bonnelykke, K., and Bisgaard, H. (2016). Picornavirus-Induced Airway Mucosa Immune Profile in Asymptomatic Neonates. *J Infect Dis* 213, 1262-1270. 10.1093/infdis/jiv594.
13. Jartti, T., Jartti, L., Peltola, V., Waris, M., and Ruuskanen, O. (2008). Identification of respiratory viruses in asymptomatic subjects: asymptomatic respiratory viral infections. *Pediatr Infect Dis J* 27, 1103-1107. 10.1097/INF.0b013e31817e695d.
14. Folsgaard, N.V., Schjorring, S., Chawes, B.L., Rasmussen, M.A., Krogfelt, K.A., Brix, S., and Bisgaard, H. (2013). Pathogenic bacteria colonizing the airways in asymptomatic neonates stimulates topical inflammatory mediator release. *Am J Respir Crit Care Med* 187, 589-595. 10.1164/rccm.201207-1297OC.
15. Coronavirus (Covid-19) Data in the United States. (2021). <https://github.com/nytimes/covid-19-data>.

16. COVID Data Tracker. <https://covid.cdc.gov/covid-data-tracker/>.
17. Grubaugh, N. (2023). CovidTrackerCT. <https://covidtrackerct.com/>.
18. Hendley, J.O., Hayden, F.G., and Winther, B. (2005). Weekly point prevalence of *Streptococcus pneumoniae*, *Haemophilus influenzae* and *Moraxella catarrhalis* in the upper airways of normal young children: effect of respiratory illness and season. *APMIS* 113, 213-220. 10.1111/j.1600-0463.2005.apm1130310.x.
19. Murphy, T.F., Faden, H., Bakaletz, L.O., Kyd, J.M., Forsgren, A., Campos, J., Virji, M., and Pelton, S.I. (2009). Nontypeable *Haemophilus influenzae* as a pathogen in children. *Pediatr Infect Dis J* 28, 43-48. 10.1097/INF.0b013e318184dba2.
20. Bogaert, D., van Belkum, A., Sluijter, M., Luijendijk, A., de Groot, R., Rumke, H.C., Verbrugh, H.A., and Hermans, P.W. (2004). Colonisation by *Streptococcus pneumoniae* and *Staphylococcus aureus* in healthy children. *Lancet* 363, 1871-1872. 10.1016/S0140-6736(04)16357-5.
21. Murphy, T.F., and Parameswaran, G.I. (2009). *Moraxella catarrhalis*, a human respiratory tract pathogen. *Clin Infect Dis* 49, 124-131. 10.1086/599375.
22. Landry, M.L., and Foxman, E.F. (2018). Antiviral Response in the Nasopharynx Identifies Patients With Respiratory Virus Infection. *J Infect Dis* 217, 897-905. 10.1093/infdis/jix648.
23. Cheemarla, N.R., Watkins, T.A., Mihaylova, V.T., Wang, B., Zhao, D., Wang, G., Landry, M.L., and Foxman, E.F. (2021). Dynamic innate immune response determines susceptibility to SARS-CoV-2 infection and early replication kinetics. *J Exp Med* 218. 10.1084/jem.20210583.
24. Cheemarla, N.R., Hanron, A., Fauver, J.R., Bishai, J., Watkins, T.A., Brito, A.F., Zhao, D., Alpert, T., Vogels, C.B.F., Ko, A.I., et al. (2023). Nasal host response-based screening for undiagnosed respiratory viruses: a pathogen surveillance and detection study. *Lancet Microbe* 4, e38-e46. 10.1016/S2666-5247(22)00296-8.

25. Aldo, P., Marusov, G., Svancara, D., David, J., and Mor, G. (2016). Simple Plex() : A Novel Multi-Analyte, Automated Microfluidic Immunoassay Platform for the Detection of Human and Mouse Cytokines and Chemokines. *Am J Reprod Immunol* 75, 678-693. 10.1111/aji.12512.
26. Baron, R.M., and Kenny, D.A. (1986). The Moderator Mediator Variable Distinction in Social Psychological-Research - Conceptual, Strategic, and Statistical Considerations. *Journal of Personality and Social Psychology* 51, 1173-1182. Doi 10.1037/0022-3514.51.6.1173.
27. Consortium, G.R. (2022). Genome Reference Consortium Human Build 38 patch release 14 (GRCh38.p14).
28. Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. *Nat Methods* 9, 357-359. 10.1038/nmeth.1923.
29. Kalantar, K.L., Carvalho, T., de Bourcy, C.F.A., Dimitrov, B., Dingle, G., Egger, R., Han, J., Holmes, O.B., Juan, Y.F., King, R., et al. (2020). IDseq-An open source cloud-based pipeline and analysis service for metagenomic pathogen detection and monitoring. *Gigascience* 9. 10.1093/gigascience/giaa111.
30. Morfin, F., Beguin, A., Lina, B., and Thouvenot, D. (2002). Detection of measles vaccine in the throat of a vaccinated child. *Vaccine* 20, 1541-1543. 10.1016/s0264-410x(01)00495-9.
31. Kobune, F., Funatu, M., Takahashi, H., Fukushima, M., Kawamoto, A., Iizuka, S., Sakata, H., Yamazaki, S., Arita, M., Xu, W., and et al. (1995). Characterization of measles viruses isolated after measles vaccination. *Vaccine* 13, 370-372. 10.1016/0264-410x(95)98259-d.
32. Kaic, B., Gjenero-Margan, I., Aleraj, B., Vilibic-Cavlek, T., Santak, M., Cvitkovic, A., Nemeth-Blazic, T., and Ivic Hofman, I. (2010). Spotlight on measles 2010: excretion of

- vaccine strain measles virus in urine and pharyngeal secretions of a child with vaccine associated febrile rash illness, Croatia, March 2010. *Euro Surveill* 15.
33. Iwasaki, A., Foxman, E.F., and Molony, R.D. (2017). Early local immune defences in the respiratory tract. *Nat Rev Immunol* 17, 7-20. 10.1038/nri.2016.117.
  34. Olsen, S.J., Winn, A.K., Budd, A.P., Prill, M.M., Steel, J., Midgley, C.M., Kniss, K., Burns, E., Rowe, T., Foust, A., et al. (2021). Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic - United States, 2020-2021. *MMWR Morb Mortal Wkly Rep* 70, 1013-1019. 10.15585/mmwr.mm7029a1.
  35. Tregoning, J.S., and Schwarze, J. (2010). Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. *Clin Microbiol Rev* 23, 74-98. 10.1128/CMR.00032-09.
  36. COVID-19 Data Resources. <https://data.ct.gov/stories/s/COVID-19-data/wa3g-tfvc/>.
  37. COVID-19 Vaccines. <https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines>.
  38. Usemann, J., Alves, M.P., Ritz, N., Latzin, P., and Müller, L. (2020). Age-dependent response of the human nasal epithelium to rhinovirus infection. *European Respiratory Journal* 56, 2000877. 10.1183/13993003.00877-2020 PMID - 32430434.
  39. Maughan, E.F., Hynds, R.E., Pennycuik, A., Nigro, E., Gowers, K.H.C., Denais, C., Gomez-Lopez, S., Lazarus, K.A., Orr, J.C., Pearce, D.R., et al. (2022). Cell-intrinsic differences between human airway epithelial cells from children and adults. *iScience* 25, 105409. 10.1016/j.isci.2022.105409.
  40. Teo, S.M., Mok, D., Pham, K., Kusel, M., Serralha, M., Troy, N., Holt, B.J., Hales, B.J., Walker, M.L., Hollams, E., et al. (2015). The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. *Cell Host Microbe* 17, 704-715. 10.1016/j.chom.2015.03.008.

41. Bosch, A., de Steenhuijsen Piters, W.A.A., van Houten, M.A., Chu, M., Biesbroek, G., Kool, J., Pernet, P., de Groot, P.C.M., Eijkemans, M.J.C., Keijser, B.J.F., et al. (2017). Maturation of the Infant Respiratory Microbiota, Environmental Drivers, and Health Consequences. A Prospective Cohort Study. *Am J Respir Crit Care Med* 196, 1582-1590. 10.1164/rccm.201703-0554OC.
42. de Steenhuijsen Piters, W.A.A., Watson, R.L., de Koff, E.M., Hasrat, R., Arp, K., Chu, M., de Groot, P.C.M., van Houten, M.A., Sanders, E.A.M., and Bogaert, D. (2022). Early-life viral infections are associated with disadvantageous immune and microbiota profiles and recurrent respiratory infections. *Nat Microbiol* 7, 224-237. 10.1038/s41564-021-01043-2.
43. Kloepfer, K.M., Lee, W.M., Pappas, T.E., Kang, T.J., Vrtis, R.F., Evans, M.D., Gangnon, R.E., Bochkov, Y.A., Jackson, D.J., Lemanske, R.F., Jr., and Gern, J.E. (2014). Detection of pathogenic bacteria during rhinovirus infection is associated with increased respiratory symptoms and asthma exacerbations. *J Allergy Clin Immunol* 133, 1301-1307, 1307 e1301-1303. 10.1016/j.jaci.2014.02.030.
44. Brealey, J.C., Chappell, K.J., Galbraith, S., Fantino, E., Gaydon, J., Tozer, S., Young, P.R., Holt, P.G., and Sly, P.D. (2018). *Streptococcus pneumoniae* colonization of the nasopharynx is associated with increased severity during respiratory syncytial virus infection in young children. *Respirology* 23, 220-227. 10.1111/resp.13179.
45. Rodrigues, F., Foster, D., Nicoli, E., Trotter, C., Vipond, B., Muir, P., Goncalves, G., Januario, L., and Finn, A. (2013). Relationships between rhinitis symptoms, respiratory viral infections and nasopharyngeal colonization with *Streptococcus pneumoniae*, *Haemophilus influenzae* and *Staphylococcus aureus* in children attending daycare. *Pediatr Infect Dis J* 32, 227-232. 10.1097/INF.0b013e31827687fc.
46. Dee, K., Goldfarb, D.M., Haney, J., Amat, J.A.R., Herder, V., Stewart, M., Szemiel, A.M., Baguelin, M., and Murcia, P.R. (2021). Human Rhinovirus Infection Blocks Severe Acute

- Respiratory Syndrome Coronavirus 2 Replication Within the Respiratory Epithelium: Implications for COVID-19 Epidemiology. *J Infect Dis* 224, 31-38. 10.1093/infdis/jiab147.
47. Dee, K., Schultz, V., Haney, J., Bissett, L.A., Magill, C., and Murcia, P.R. (2022). Influenza A and respiratory syncytial virus trigger a cellular response that blocks severe acute respiratory syndrome virus 2 infection in the respiratory tract. *J Infect Dis*. 10.1093/infdis/jiac494.
  48. Oishi, K., Horiuchi, S., Minkoff, J.M., and tenOever, B.R. (2022). The Host Response to Influenza A Virus Interferes with SARS-CoV-2 Replication during Coinfection. *J Virol* 96, e0076522. 10.1128/jvi.00765-22.
  49. Wu, A., Mihaylova, V.T., Landry, M.L., and Foxman, E.F. (2020). Interference between rhinovirus and influenza A virus: a clinical data analysis and experimental infection study. *Lancet Microbe* 1, e254-e262. 10.1016/s2666-5247(20)30114-2.
  50. Essaidi-Laziosi, M., Alvarez, C., Puhach, O., Sattonnet-Roche, P., Torriani, G., Tapparel, C., Kaiser, L., and Eckerle, I. (2022). Sequential infections with rhinovirus and influenza modulate the replicative capacity of SARS-CoV-2 in the upper respiratory tract. *Emerg Microbes Infect* 11, 412-423. 10.1080/22221751.2021.2021806.
  51. Lu, X., Wang, L., Sakthivel, S.K., Whitaker, B., Murray, J., Kamili, S., Lynch, B., Malapati, L., Burke, S.A., Harcourt, J., et al. (2020). US CDC Real-Time Reverse Transcription PCR Panel for Detection of Severe Acute Respiratory Syndrome Coronavirus 2. *Emerg Infect Dis* 26, 1654-1665. 10.3201/eid2608.201246.
  52. Tingley, D., Yamamoto, T., Hirose, K., Keele, L., and Imai, K. (2014). mediation: R Package for Causal Mediation Analysis. *Journal of Statistical Software* 59.
  53. Team, R.C. (2021). R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing).

54. Wickham, H., Averick, M., Bryan, J., Chang, W., McGowan, L.D.A., François, R., Grolemond, G., Hayes, A., Henry, L., and Hester, J. (2019). Welcome to the Tidyverse. *Journal of open source software* 4, 1686.
55. Grolemond, G., and Wickman, H. (2011). Dates and Times Made Easy with lubridate. *Journal of Statistical Software* 40, 1-25.
56. Wickham, H. (2011). ggplot2. *Wiley interdisciplinary reviews: computational statistics* 3, 180-185.
57. Cunningham, F., Allen, J.E., Allen, J., Alvarez-Jarreta, J., Amode, M.R., Armean, I.M., Austine-Orimoloye, O., Azov, A.G., Barnes, I., Bennett, R., et al. (2022). Ensembl 2022. *Nucleic Acids Res* 50, D988-D995. [10.1093/nar/gkab1049](https://doi.org/10.1093/nar/gkab1049).



## **Figures and Tables**

### **Figures**

**Figure 1:** Study overview.

**Figure 2:** SARS-CoV-2, non-SARS-CoV-2 respiratory virus, and bacterial pathobiont test results.

**Figure 3:** Relationship between viral load, age, and nasopharyngeal CXCL10 level in pediatric subjects ages 0-19 years.


**Figure 4:** Nasopharyngeal innate immune response and viral load in SARS-CoV-2+ subjects with and without co-infecting respiratory viruses

**Figure 5:** Immunophenotyping of nasal mucosal innate response in children <5 years.


### **Tables**

**Table 1:** Results of multiplex virology testing by demographics, presentation, and pathobiont status.

## Figures and Legends













**Figure 1: Study overview.** Nasopharyngeal swab samples from subjects ages 0-19 undergoing SARS-CoV-2 testing in the YNHH pediatric E.D. or pre-operative screening were collected from January 11-23, 2022 and processed/analyzed as indicated.




**Figure 2: SARS-CoV-2, non-SARS-CoV-2 respiratory virus, and bacterial pathobiont test results.**

- (A) Number of samples testing negative for 16 respiratory viruses (white) positive for non-SARS-CoV-2 respiratory virus (grey) or SARS-CoV-2 (black) by age and clinical presentation.
- (B) Number of samples negative for viruses and bacteria (white), positive for virus only (dark grey), pathobiont only (light grey), or virus/pathobiont double positive (black) by age and clinical presentation. See Tables S1-5 for additional information.

**A CXCL10 vs Age****B****C All virus-positive****D****E****F SARS-CoV-2+****G****H**


**Figure 3: Relationship between viral load, age, and nasopharyngeal CXCL10 level in pediatric subjects ages 0-19 years.**

- (A) Correlation between CXCL10 (Log10 pg/mL) in virus-positive subjects (black line), virus negative subjects (grey line), and all subjects (dashed line). For A and C-H, shading represents 95% CI for regression line slope,  $r^2$  and p-value for correlation are shown.
- (B) Nasopharyngeal CXCL10 (Log10 pg/mL) in virus-positive and virus-negative subjects of all ages (n=291). P-value by Welch's t-test is shown.
- (C) CXCL10 (Log10 pg/mL) versus viral load (Ct value), all virus-positive samples. For samples with >1 virus detected, plot shows highest viral load (lowest Ct value).
- (D) CXCL10 (Log10 pg/mL) versus age, all virus-positive samples,
- (E) Viral load versus age, all virus-positive samples. For samples with >1 virus detected, plot shows highest viral load (lowest Ct value).
- (F) Viral load in SARS-CoV-2 single infections versus CXCL10 (Log10 pg/mL).
- (G) CXCL10 level (Log10 pg/mL) versus age for SARS-CoV-2 single infections.
- (H) Viral load versus age for SARS-CoV-2 single infections.
- (I) Mediation analysis results for Ct value in single infection or lowest Ct value in coinfection as a mediator between age and CXCL10. Figure shows average causal mediation effect (ACME) through viral load denoted by curved arrow (-0.05 [-0.08, -0.03 CI],  $p < 0.001$ ), average direct effect of age on CXCL10 (-0.0106 [-0.0476, 0.03],  $p = 0.570$ ), shown in italics. 95% confidence intervals for mediation analysis are derived from 1000 bootstrapped samples.
- (J) Mediation analysis results for SARS-CoV-2 viral load (Ct) as a mediator between age and CXCL10. Figure shows average causal mediation effect (ACME) through viral load denoted by curved arrow (-0.05 [-0.09, -0.02 CI],  $p = 0.002$ ), average direct effect of age on CXCL10 (-0.0307 [-0.0855, 0.03],  $p = 0.268$ ), shown in italics. 95% confidence intervals for mediation analysis are derived from 1000 bootstrapped samples.



**Figure 4: Relationship between nasopharyngeal innate immune response and viral load in SARS-CoV-2+ subjects with and without co-infecting respiratory viruses.**

- (A) Viral load vs. nasal CXCL10 ( $\text{Log}_{10}$  pg/mL) concentration for pediatric SARS-CoV-2+ samples with and without viral coinfections in this study. Regression line is calculated for CXCL10 and viral load of SARS-CoV-2+ positive samples without viral coinfections (grey dots). Colored dots show viral load vs. CXCL10 SARS-CoV-2+ samples with viral coinfections. Dots are labeled with co-infecting virus and respective viral load based on the color scale. RV=rhinovirus; IAV=influenza A virus; CoV=seasonal coronavirus; HMPV=human metapneumovirus; RSV=respiratory syncytial virus.
- (B) Viral load vs. nasal RNA-seq ISG score for SARS-CoV-2+ samples with and without viral coinfections from children (circles) and adults (squares), GSE17274 dataset. Regression line is calculated for ISG score and viral load for SARS-CoV-2+ positive samples without viral coinfections (grey symbols). Colored symbols show samples with viral coinfections. The red asterisk denotes a patient with reads from attenuated measles vaccine virus. See Table S6 for additional information.



**Figure 5: Immunophenotyping of nasal mucosal innate response in children <5 years.**

(A) Nasal IL-1 $\beta$  protein concentration (Log<sub>10</sub>pg/mL) in 135 nasopharyngeal samples from children under 5 years with or without viruses or pathobiome detected. P-values based on Welch's ANOVA test with Dunnett's T3 multiple comparisons tests are shown. ns=not significant.

- (B) Nasal TNF protein concentration ( $\text{Log}_{10}\text{pg/mL}$ ) in virus-/pathobiont-, virus-/pathobiont+, virus+/pathobiont-, and virus+/pathobiont+ samples. P-values for groups with significant differences based on Kruskal-Wallis test with Dunn's multiple comparisons tests are shown. Ns=not significant
- (C) IL-1 $\beta$  ( $\text{Log}_{10}\text{pg/mL}$ ) vs. pathobiont load (Ct value) in pathobiont-positive samples. For samples with >1 pathobiont detection, lowest Ct value is plotted. Simple linear regression with 95% confidence bands is plotted for D-F.
- (D) IL-1 $\beta$  ( $\text{Log}_{10}\text{pg/mL}$ ) vs. *M. catarrhalis* load (Ct value) in samples positive for *M. catarrhalis* only and no other pathobionts.
- (E) TNF ( $\text{Log}_{10}\text{pg/mL}$ ) vs. pathobiont load (Ct value). Points show virus-negative samples (open circles), virus-positive samples (black circles). Linear regression for virus-negative samples (grey line) and virus-positive samples (black line) are shown. P-value for difference between slopes is shown ( $p=0.1055$ , n.s.).
- (F) CXCL10 protein concentration ( $\text{Log}_{10}\text{pg/mL}$ ) in virus-/pathobiont-, virus-/pathobiont+, virus+/pathobiont-, and virus+/pathobiont+ samples. P-values based on Welch's ANOVA test with Dunnett's T3 multiple comparisons tests are shown. ns=not significant. Statistical comparisons are made using the Welch's ANOVA test with Dunnett's T3 multiple comparisons tests.
- (G) –(J)  $\text{Log}_{10}\text{CXCL10}$  vs.  $\text{Log}_{10}\text{IL1-}\beta$  for subjects <5 years of age ( $n=135$ ). Color scaled by age (G), viral Ct (H), bacterial Ct (I), and symptom status (J). For (J), ellipses cover 80% of points in each group. See figures S3-5 for additional information.



	<b>Overall</b>	<b>Virus-Negative</b>	<b>Virus-Positive</b>	<b>p-value</b>
N	291	185	106	
<b>Sex</b>				<b>0.111</b>
Male	144	85	59	
Female	147	100	47	
<b>Median Age</b>	<b>5.8</b>	<b>9.3</b>	<b>2.85</b>	<b>&lt;0.0001</b>
<b>Presentation</b>				<b>&lt;0.0001</b>
Symptomatic	108	35	73	
Asymptomatic	183	150	33	
<b>Pathobiont Status</b>				<b>&lt;0.0001</b>
Negative	183	136	47	
Positive	107	49	58	

**Table 1: Results of multiplex virology testing by demographics, presentation, and pathobiont status.**

Viral PCR results are shown with respect to biological sex, age, symptoms, and pathobiont status. P values based on Chi-square tests show relationship between number of virus positives and biological sex, symptoms, and pathobiont status. The Mann-Whitney test is used to compare number of virus positives by age. See Tables S3-5 for additional information.